Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 10, 2004, Pages 2115-2126

  Amato, Maria Pia ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Disease modifying therapies; Economic evaluation; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NEUTRALIZING ANTIBODY; PLACEBO; STEROID;

ACCURACY; ANTIBODY PRODUCTION; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DECUBITUS; DISABILITY; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; ECONOMIC EVALUATION; GEOGRAPHY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; MULTIPLE SCLEROSIS; MUSCLE CONTRACTURE; PHYSIOTHERAPY; PREVALENCE; PSYCHOTHERAPY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; SOCIAL SUPPORT; URINARY TRACT INFECTION;

ADJUVANTS, IMMUNOLOGIC; COST OF ILLNESS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; EUROPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MITOXANTRONE; MULTIPLE SCLEROSIS; NORTH AMERICA; PEPTIDES;

EID: 6444224857     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.10.2115     Document Type: Review

References (57)

1. NOSEWORTHY JH, LUCCHINETTI C, RODRIGUEZ M, WEINSHENKER BG: Multiple sclerosis. N. Engl. J. Med. (2000) 343(13 ):939-952.
2. PUGLIATTI M, SOTGIU S, ROSATI G: The worldwide prevalence of multiple sclerosis. Clin. Neurol. Neurosurg. (2002) 104 3):182-191.
3. AMATO MP, PONZIANI G: Quantification of impairment in MS: discussion of the scales in use. Mult. Scler. (1999) 5 4):216-219.
4. KURTZKE JF: Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 33(11):1444-1452.
5. GRIMAUD J, AURAY JP, COLLECTIF SEP DES VILLES ET SEP DES CHAMPS: Quality of life and economic cost of multiple sclerosis. Rev. Neurol. (2004) 160(1):23-34.
6. THE IFN-β MULTIPLE SCLEROSIS STUDY GROUP: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology (1993) 43(4):655-661.
7. JACOBS LD, COOKFAIR DL, RUDICK RA et al.: Intramuscolar interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann. Neurol. (1996) 39(3):285-294.
8. PRISMS (PREVENTION OF RELAPSES AND DISABILITY BY INTERFERON BETA-1A SUBCUTANEOUSLY IN MULTIPLE SCLEROSIS) STUDY GROUP: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet (1998) 352 9139):1498-1504.
9. JOHNSON KP, BROOKS BR, COHEN JA et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of the Phase III multicenter, doubleblind, placebo-controlled trial. Neurology (1995) 45(7):1268-1276.
10. EUROPEAN STUDY GROUP ON INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MS: Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet (1998) 352(9139):1491-1497.
11. HARTUNG HP, GONSETTE R, KONIG N et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet (2002) 360 9350):2018-2025.
12. GOODIN DS, FROHMAN EM, GARMANY GP JR et al.: Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology (2002) 58(2):169-178.
13. PANITCH H, GOODIN DS, FRANCIS G et al.: Evidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology (2002) 59(10):1496-1506.
14. DURELLI L, VERDUN E, BARBERO P et al.: Every-other-day interferon beta-1b versus once-weekly interferon beta 1-a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet (2002) 359(9316):1453-1460.
15. JACOBS LD, BECK RW, SIMON JH et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. (2000) 343(13):898-904.
16. COMI G, FILIPPI M, BARKHOF F et al.: Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 357(9268):1576-1582.
17. FILIPPINI G, MUNARI L, INCORVAIA B et al.: Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet (2003) 361(9357):545-552.
18. GRUDZINSKI AN, HAKIM Z, COX ER, BOOTMAN JL: The economics of multiple slerosis. Distribution of costs and relationship to disease severity. Pharmacoeconomics (1999) 15(3):229-240.
19. HENRIKSSON F, JONSSON B: The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics (1998) 13 597-606.
20. HOLMES BA, MADGKICK T, BATES D: The cost of MS. Br. J. Med. Econ. (1995) 8:181-193.
21. BLUMHARDT L, WOOD C: The economics of multiple sclerosis: a cost of illness study. Br. J. Med. Econ. (1996) 10:99-118.
22. CARTON H, LOOS R, PACOLET J, VERSIECK K, VLIETINCK R: Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J. Neurol. Neurosurg. Psychiatry (1998) 64(4):444-450.
23. MURPHY N, CONFAVREUX C, HAAS J et al.: Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics (1998) 13:607-622.
24. AMATO MP, BATTAGLIA MA, CAPUTO D et al.: for the Mu. S. I. C. Study Group. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J. Neurol. (2002) 249(2):152-163.
25. RUSSO P, CAPONE A, PAOLILO A et al.: Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of the new disease-modifying agents. Clin. Drug Invest. (2004) 24 7):421-432.
26. INMAN RP: Disability indices, the economic costs of illness and social insurance: the cost of MS. Acta Neurol. Scand. (1984) 101:46-55.
27. BOURDETTE DN, PROCHAZKA AV, MITCHELL W, LICARI P, BURKS J: Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group. Arch. Phys. Med. Rehab. (1993) 74(1):26-31.
28. WHETTEN-GOLDSTEIN K, SLOAN FA, GOLDSTEIN LB, KULAS ED: A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult. Scler. (1998) 4(5):419-425.
29. POPE GC, URATO CJ, KULAS ED et al.: Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology (2002) 58(1):37-43.
30. ASCHE CV, HO E, CHAN B, COYTE PC: Economic consequences of multiple sclerosis for Canadians. Acta Neurol. Scand. (1997) 95 5):268-274.
31. CLEGG A, BRYANT J, MILNE R: Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol. Assess. (2000) 4(9):i-iv, 1-101.
32. HOLLOWAY RG: Cost-effectiveness analysis: what is it and how will it influence neurology. Ann. Neurol. (1996) 39 6):818-823.
33. RICHARDS RG, SAMPSON FC, BEARD SM, TAPPENDEN P: A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol. Assess. (2002) 6(10):iii-73.
34. PARKIN D, MCNAMEE P, JACOBY A et al.: A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol. Assess. (1998) 2(4):iii-54.
35. PARKIN D, JACOBY A, MCNAMEE P, MILLER P, THOMAS S, BATES D: Treatment of multiple sclerosis with interferon β: an appraisal of cost-effectiveness and quality of life. J. Neurol. Neurosurg. Psychiatr. (2000) 68(2):144-149.
36. VICKREY BG, HAYS RD, HAROONI R et al.: A health-related quality of life measure for multiple sclerosis. Qual. Life Res. (1995) 4(3):187-206.
37. WILLIAMS A: The role of the EUROQoL instrument in QALY calculations. York: University of York, Centre for Health Economics (1995).
38. FORBES RB, LEES A, WAUGH N, SWINGLER RJ: Population-based cost utility study of interferon beta 1b in secondary progressive multiple sclerosis. Br. Med. J. (1999) 319(7224):1529-1533.
39. NUIJTEN MJ, HUTTON J: Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health (2002) 5(1):44-54.
40. BROWN MG, MURRAY TJ, SKETRIS IS et al.: Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression: first estimates. Int. J. Technol. Assess. Health Care (2000) 16(3):751-767.
41. SKETRIS IS, BROWN MG, MURRAY TJ, FISK JD, MCLEAN K: Drug therapy in multiple sclerosis. A study of Nova Scotia Senior citizens. Clin. Ther. (1996) 18(2):303-318.
42. KENDRICK M, JOHNSON KI: Long-term treatment of multiple sclerosis with interferon-â may be cost effective. Pharmacoeconomics (2000) 18(1):45-53.
43. PHILLIPS CJ, GILMOUR L, GALE R, PALMER M: A cost utility model of interferon beta 1b in the treatment of relapsing-remitting multiple sclerosis. J. Med. Econ. (2001) 4:35-50.
44. KOBELT G, JONSSON L, HENRIKSSON F, FREDRIKSON S, JONSSON B: Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. Int. J. Technol. Assess. Health Care (2000) 16(3):768-780.
45. KOBELT G, JONSSON L, MILTENBURGER C, JONSSON B: Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis using natural history disease data. Int. J. Technol. Assess. Health Care (2002) 18(1):127-138.
46. WEINSHENKER BG, BRASS B, RICE GP et al.: The natural history of multiple sclerosis: A geographically based study, I: Clinical course and disability. Brain (1989) 112(6):133-146.
47. WEINSHENKER BG, RICE GP, NOSEWORTHY JH et al.: The natural history of multiple sclerosis: a geographically based study. 2. Multivariate analysis of predictive factors and models of outcome. Brain (1991) 114(2):1045-1056.
48. NICHOLSON T, MILNE R: Copolymer 1 in relapsing-remitting multiple sclerosis. Southampton:Wessex Institute for Health Research and Development, Development and Evaluation Committee (1996) Report no. 63.
49. BOSE U, LADKANI D, BURRELL A, SHARIEF M: Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. J. Med. Econ. (2001) 4:207-219.
50. TOUCHETTE DR, DURGIN TL, WANKLE LA, AND GOODKIN DE: A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in secondary progressive or progressive-relapsing multiple sclerosis. Clin. Ther. (2003) 25(2):611-634.
51. RUBIO-TERRES C, ARISTEGUI RI, MEDINA REDONDO F, IZQUIERDO A: Cost-utility analysis of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain. Farm. Hosp. (2003) 27 3):159-165.
52. HOLLENDORF DA, JILINSKAIA E, OLEEN-BURKEY M: Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J. Manag. Care Pharm. (2002) 8(6):469-476.
53. CHILCOTT J, MCCABE C, TAPPENDEN P et al.: Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Br. Med. J. (2003) 326 7388):522-527.
54. PATZOLD U, POCKLINGTON PR: Course of multiple sclerosis: first results of a prospective study carried out on 102 MS patients from 1976-80. Acta Neurol. Scand. (1982) 65(4):248-266.
55. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis: Technology Appraisal Guidance N° 32. London: National Institute for Clinical Excellence (2002).
56. DEVLIN N, APPLEBY J, PARKIN D: Patients' views of explicit rationing: what are the implications for health service decision-making? J. Health Serv. Res. Policy (2003) 8(3):183-186.
57. Department of Health: Faster access to modern treatments: how NICE will work. London: HMSO (1999).